Table 1 Characteristics of studies included in the AR-V7-positive proportion meta-analysis
Author | Year | Country | Â | Newly diagnosed PCa | CRPC | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | AR-V7 detection assay | Patients (n) | Age (range) | Gleason score (range) | Median PSA (ng/ml) at sampling (range) | Patients (n) | Age (range) | Gleason score (range) | Median PSA (ng/ml) at sampling (range) | Follow-up time (month) Median (range) |
Horenberg [19] | 2011 | Sweden | Tissue RNA | 10 | 79 (60–85) | - | 156 (21–10,000) | 30 | 73 (54–88) | - | 335 (4–5139) | - |
Hu [6] | 2009 | USA | Tissue RNA | 82 | - | - | - | 25 | - | 7 (5–9) | - | - |
Qu [15] | 2015 | China | IHC | 104 | 70 (43–84) | 8 | 122.5 (3.0–6006.2) | 46 | 65 (50–79) | 8 | 98 (2.6–2350.0) | 25 (2–132) |
Welti [24] | 2016 | UK | IHC | 33 | - | - | - | 35 | 67.5 (IQR64.2–75.3) | - | - | - |
Zhang [32] | 2011 | USA | IHC | 50 | - | - | - | 162 | 63 (42–93) | - | 12.4 (1.7–4000) | - |
Zhu [ 21] | 2018 | USA | RISH | 9 | - | - | - | 28 | 64 (52-86) | - | 59.6 (0.7-6746.8) | Â |
UK | RISH | 0 | - | - | - | 16 | 72.3 (48.8-79.4) | - | 177.0 (2.6-4098.0) | Â | ||
Takeuchi [ 28] | 2016 | Japan | Whole blood RNA | 20 | Â | - | - | 23 | - | - | - | - |
Lee [30] | 2017 | Korea | Tissue RNA | 13 | - | 7 (6-9) | 12.76 (2.75-40.92) | 3 | 65.3 (56-70) | 8 (8-10) | 8.78 (8.6-173.7) | - |
Saylor [22] | 2017 | USA | RISH | 30 | - | 7 (6–10) |  | 12 | - | - | - | - |
Kallio [23] | 2018 | Finland | IHC/RNA-seq | 24 | - | 7 | 6.3 (4.1-21.0) | 30 | - | - | - | - |
Nimir [26] | 2019 | Australia | CTC RNA/ctRNA/Exosome RNA | 12 | - | - | - | 32 | - | - | - | - |
Sharp [40] | 2019 | USA | IHC- | |||||||||
ICR/RMH | 63 | 61.7 (SD=7.52) | >7 (67%) | 51.7 (IQR 20.3-145.0) | 160 | 68.5 (IQR 63.9-73.1) | - | 230.5 (IQR 77.0-591.5) | - | |||
UW | 128 | 60 (SD=8.21) | >7 (70%) | 6.3 (IQR 3.3-67.0) | - | - | - | - | ||||
Woo [29] | 2018 | Korea | Urinary Exosome RNA | 22 | 70 (51-84) | >7 (14%) | 1.01 (0.005-1667) | 14 | 71.5 (60-82) | >7 (71.5%) | 19.38 (0.006-646) | - |
Park [31] | 2019 | Korea | Tissue RNA | 19 | 65.9 (52-79) | >7 (58%) | - | 19 | - | >7(84%) | - | 46(1-158) |
Nakazawa [27] | 2015 | USA | CTC mRNA | 2 | 53.5 (50–57) | 9 | 339.5 (314–365) | 12 | 67 (56-82) | >8 (91.7%) | 159.5 (2.2-895) | 11 (6–18) |